SMS Pharmaceuticals Limited has informed the Exchange about General Updates

Regulatory Product ApprovalBusiness Updates View source PDF Explain this filing

SMSPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+3.6%Reaction day

₹239.00

prior close

₹248.90

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.0%+3.5% vs market

Pharmaceuticals peers, median of 151sector-0.2%+3.7% vs sector

On the reaction day the stock moved 3.5 pts more than Nifty Microcap 250 and 3.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.8

10m

+1.2

15m

+1.6

30m

+1.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+3.6+0.0+3.5-0.2+3.7

Next day

+4.2+0.5+3.7+0.3+3.9

+5.2+1.4+3.8+1.2+4.0

+2.9+1.5+1.4+0.9+2.0

-0.4+1.3-1.7+1.0-1.4

+1.6+1.4+0.2+1.3+0.3

+1.3+1.3-0.1+0.8+0.4

15d

+3.7+3.7-0.1+3.9-0.2

+0.4-0.8+1.2+1.0-0.6

-3.3-2.8-0.5-3.6+0.3

+6.2-2.9+9.1-2.9+9.1

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 151Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

SMS Pharmaceuticals has successfully completed its second USFDA inspection at its Central Laboratory Analytical Services facility in Gagillapur, Hyderabad. The inspection ran from June 23 to June 25, 2025, and concluded with zero Form 483 observations, meaning the US drug regulator found no adverse issues during the audit. This was the second consecutive clean inspection for this independent testing lab. The company highlighted its commitment to CGMP and GLP compliance standards across all its manufacturing and analytical facilities.

Likely market impact

Positive signal for shareholders — a clean USFDA inspection strengthens the company's credibility with global regulators and supports its ability to serve US export markets. This can boost investor confidence but typically does not cause an immediate sharp move in the stock price.